Shopping Cart 0
Cart Subtotal
AED 0

Janssen Biotech Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Janssen Biotech Inc (Janssen), formerly Centocor Ortho Biotech Inc. is a subsidiary of Johnson & Johnson, pharmaceutical company that manufactures, develops, and markets prescription drugs in immunology, nephrology and oncology areas. The company offers products such as stelara ustekinumab, simponi aria golimumab, remicade infliximab, procrit epoetin alfa, m doxil doxorubicin HCl liposome injection and zytiga abiraterone acetate. Its products are used for the treatment of infections that include muscle aches, cough, shortness of breath, fever, sweats, blood in phlegm, weight loss and stomach pain. The company also provides medical information database and reimbursement resources. Janssen is headquartered in Horsham, Pennsylvania, the US.

Janssen Biotech Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

Janssen Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11

Janssen Biotech Inc, Medical Devices Deals, 2011 to YTD 2017 13

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deal Details 19

Partnerships 19

Janssen Biotech Enters into Partnership with Bristol-Myers 19

Janssen Biotech Partners with Weill Cornell Medicine to Develop Prostate Cancer Therapies 19

Karolinska Institutet Partners with Johnson & Johnson Companies 20

Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 21

HitGen Enters into Agreement with Janssen Biotech 21

Innovative Targeting Solutions Enters into Research Agreement with Janssen Biotech 22

Philogen Enters into Co-Development Agreement with Janssen Biotech 23

Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech 24

Amyris Enters into Research Agreement with Janssen Biotech 24

Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 25

Enterome Bioscience Enters into Research Agreement with Janssen Biotech 26

Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 27

Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 27

Janssen Biotech Enters into Agreement with HUB foundation 28

Janssen Biotech Enters into Agreement with Eureka Therapeutics 29

Nuevolution Enters into Discovery Agreement with Janssen Biotech 29

enGene Enters into Agreement with Janssen Biotech 30

OICR and Novera Therapeutics Enter into Co-Development Agreement with Janssen Biotech 31

UbiVac Enters into Agreement with Janssen Biotech 32

Protectimmun Enters into Research Agreement with Janssen Biotech And Imperial College 33

Nextera Enters into Research Agreement with Janssen Biotech 33

Janssen Biotech Enters into Research Agreement with Emulate 34

X-Chem Expands Agreement with Janssen Biotech 35

Vectura Enters into Development and License Agreement with Janssen Biotech 36

Isis Pharma Enters into Agreement with Janssen Biotech to Discover and Develop RNA-Targeted Therapeutics 36

Atreca Enters into Research Agreement with Janssen Biotech 37

Weill Cornell Medical College Enters into Co-Development Agreement with Janssen Biotech and Johnson & Johnson Innovation 38

University of Texas MD Anderson Cancer Center Enters Into Co-Development Agreement With Johnson & Johnson Innovation And Janssen Biotech 39

Scholar Rock Enters Into Research Collaboration With Johnson & Johnson Innovation And Janssen Biotech 40

Capricor Enters Into Co-Development Agreement With Janssen For Cell Therapy For Cardiovascular Applications 41

Second Genome Enters Into Agreement With Janssen Biotech For Microbiome Drug Discovery 42

Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 43

Araxes Pharma Enters Into Drug Discovery Agreement With Janssen Biotech For Cancer 44

FORMA Therapeutics Enters Into Co-Development Agreement With Janssen Biotech 45

Molecular Partners Enters Into Research Agreement With Janssen Biotech 46

Topivert Enters into Drug Discovery Collaboration Agreement with RespiVert 47

Licensing Agreements 48

Janssen Biotech Enters into Licensing Agreement with Trianni 48

Janssen Biotech Enters into Licensing Agreement with Ablexis 48

CPDC Enters into Licensing Agreement with Janssen Biotech for Centyrin 49

Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 50

Janssen Biotec Enters into Licensing Agreement with MacroGenics 51

Janssen Biotech Enters into Licensing agreement with Tesaro 52

Janssen Biotech Exercises Option for Licensing Agreement with X-Chem 53

ViaCyte Enters into Licensing Agreement with Janssen Biotech 53

Janssen Biotech Exercises Option for Licensing Agreement with Scholar Rock 54

Janssen Biotech to Enter into Licensing Agreement with Alligator Bioscience for ADC-1013 55

Poseida Therapeutics Enters into Licensing Agreement with Janssen Biotech 56

Poseida Therapeutics Enters into Licensing Agreement with Janssen 57

Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 58

Applied Molecular Transport Enters into Licensing Agreement with Janssen Biotech 59

MacroGenics Enters into Licensing Agreement with Janssen Biotech for MGD011 59

Vedanta Biosciences Enters into Licensing Agreement with Janssen Biotech 61

Halozyme Therapeutics Enters into Licensing Agreement with Janssen Biotech 62

Geron Enters into Licensing Agreement with Janssen Biotech for Imetelstat 63

Modern Biosciences Enters into Licensing Agreement with Janssen Biotech 65

Transposagen BioPharma Enters into Licensing Agreement with Janssen Biotech 66

Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 67

Aduro BioTech Enters into Exclusive Licensing Agreement with Janssen Biotech 68

Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 69

Amunix Expands Licensing Agreement With Janssen For XTEN Technology 70

CSL Enters Into Licensing Agreement With Janssen For CSL-362 71

Genmab Expands Licensing Agreement With Janssen Biotech 72

Janssen Biotech Exercises Option for Licensing Agreement with OSE Immunotherapeutics 73

Amunix Exercises Option For Licensing Agreement With Janssen Biotech For XTEN Technology 74

Janssen Biotech Exercises Option For Licensing Agreement With Forma Therapeutics 75

Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 76

Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 77

Amunix Enters Into Licensing Agreement With Janssen Biotech For Proprietary XTEN Technology 78

Phenex Pharma Enters Into Licensing Agreement With Janssen Biotech For Retinoid-Acid Receptor-Related Orphan Receptor Gamma t Program 79

Janssen Biotech to Terminate Licensing Agreement with Astellas Pharma for ASP015K 80

Genmab Enters Into Licensing Agreement With Janssen Biotech For Daratumumab 81

ImmuNext Enters Into Licensing Agreement With Janssen Biotech 83

Genmab Enters Into Licensing Agreement With Janssen Biotech For DuoBody Technology 84

Phylogica Enters Into Licensing Agreement With Janssen Biotech For Phylomer Technology 84

Metamark Genetics Enters Into Licensing Agreement With Janssen Biotech 85

Janssen Biotech Enters Into Licensing Agreement With Pharmacyclics For PCI-32765 86

Topivert Enters into Licensing Agreement with RespiVert 88

AVEO Pharma Enters Into Licensing Agreement With Centocor Ortho Biotech 88

Acquisition 90

Janssen Biotech Enters Into Option To Acquire Amphivena From Affirmed Therapeutics 90

Janssen Biotech To Acquire Vascular Pharma, Diabetes Drug Developer 91

Janssen Biotech Inc-Key Competitors 93

Key Employees 94

Locations And Subsidiaries 95

Head Office 95

Other Locations & Subsidiaries 95

Appendix 96

Methodology 96

About GlobalData 96

Contact Us 96

Disclaimer 96


List Of Figure

List of Figures

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 9

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11

Janssen Biotech Inc, Medical Devices Deals, 2011 to YTD 2017 13


List Of Table

List of Tables

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Key Facts 1

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

Janssen Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Janssen Biotech Inc, Deals By Therapy Area, 2011 to YTD 2017 11

Janssen Biotech Inc, Medical Devices Deals, 2011 to YTD 2017 13

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14

Janssen Biotech Enters into Partnership with Bristol-Myers 19

Janssen Biotech Partners with Weill Cornell Medicine to Develop Prostate Cancer Therapies 19

Karolinska Institutet Partners with Johnson & Johnson Companies 20

Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 21

HitGen Enters into Agreement with Janssen Biotech 21

Innovative Targeting Solutions Enters into Research Agreement with Janssen Biotech 22

Philogen Enters into Co-Development Agreement with Janssen Biotech 23

Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech 24

Amyris Enters into Research Agreement with Janssen Biotech 24

Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 25

Enterome Bioscience Enters into Research Agreement with Janssen Biotech 26

Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 27

Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 27

Janssen Biotech Enters into Agreement with HUB foundation 28

Janssen Biotech Enters into Agreement with Eureka Therapeutics 29

Nuevolution Enters into Discovery Agreement with Janssen Biotech 29

enGene Enters into Agreement with Janssen Biotech 30

OICR and Novera Therapeutics Enter into Co-Development Agreement with Janssen Biotech 31

UbiVac Enters into Agreement with Janssen Biotech 32

Protectimmun Enters into Research Agreement with Janssen Biotech And Imperial College 33

Nextera Enters into Research Agreement with Janssen Biotech 33

Janssen Biotech Enters into Research Agreement with Emulate 34

X-Chem Expands Agreement with Janssen Biotech 35

Vectura Enters into Development and License Agreement with Janssen Biotech 36

Isis Pharma Enters into Agreement with Janssen Biotech to Discover and Develop RNA-Targeted Therapeutics 36

Atreca Enters into Research Agreement with Janssen Biotech 37

Weill Cornell Medical College Enters into Co-Development Agreement with Janssen Biotech and Johnson & Johnson Innovation 38

University of Texas MD Anderson Cancer Center Enters Into Co-Development Agreement With Johnson & Johnson Innovation And Janssen Biotech 39

Scholar Rock Enters Into Research Collaboration With Johnson & Johnson Innovation And Janssen Biotech 40

Capricor Enters Into Co-Development Agreement With Janssen For Cell Therapy For Cardiovascular Applications 41

Second Genome Enters Into Agreement With Janssen Biotech For Microbiome Drug Discovery 42

Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 43

Araxes Pharma Enters Into Drug Discovery Agreement With Janssen Biotech For Cancer 44

FORMA Therapeutics Enters Into Co-Development Agreement With Janssen Biotech 45

Molecular Partners Enters Into Research Agreement With Janssen Biotech 46

Topivert Enters into Drug Discovery Collaboration Agreement with RespiVert 47

Janssen Biotech Enters into Licensing Agreement with Trianni 48

Janssen Biotech Enters into Licensing Agreement with Ablexis 48

CPDC Enters into Licensing Agreement with Janssen Biotech for Centyrin 49

Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 50

Janssen Biotec Enters into Licensing Agreement with MacroGenics 51

Janssen Biotech Enters into Licensing agreement with Tesaro 52

Janssen Biotech Exercises Option for Licensing Agreement with X-Chem 53

ViaCyte Enters into Licensing Agreement with Janssen Biotech 53

Janssen Biotech Exercises Option for Licensing Agreement with Scholar Rock 54

Janssen Biotech to Enter into Licensing Agreement with Alligator Bioscience for ADC-1013 55

Poseida Therapeutics Enters into Licensing Agreement with Janssen Biotech 56

Poseida Therapeutics Enters into Licensing Agreement with Janssen 57

Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 58

Applied Molecular Transport Enters into Licensing Agreement with Janssen Biotech 59

MacroGenics Enters into Licensing Agreement with Janssen Biotech for MGD011 59

Vedanta Biosciences Enters into Licensing Agreement with Janssen Biotech 61

Halozyme Therapeutics Enters into Licensing Agreement with Janssen Biotech 62

Geron Enters into Licensing Agreement with Janssen Biotech for Imetelstat 63

Modern Biosciences Enters into Licensing Agreement with Janssen Biotech 65

Transposagen BioPharma Enters into Licensing Agreement with Janssen Biotech 66

Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 67

Aduro BioTech Enters into Exclusive Licensing Agreement with Janssen Biotech 68

Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 69

Amunix Expands Licensing Agreement With Janssen For XTEN Technology 70

CSL Enters Into Licensing Agreement With Janssen For CSL-362 71

Genmab Expands Licensing Agreement With Janssen Biotech 72

Janssen Biotech Exercises Option for Licensing Agreement with OSE Immunotherapeutics 73

Amunix Exercises Option For Licensing Agreement With Janssen Biotech For XTEN Technology 74

Janssen Biotech Exercises Option For Licensing Agreement With Forma Therapeutics 75

Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 76

Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 77

Amunix Enters Into Licensing Agreement With Janssen Biotech For Proprietary XTEN Technology 78

Phenex Pharma Enters Into Licensing Agreement With Janssen Biotech For Retinoid-Acid Receptor-Related Orphan Receptor Gamma t Program 79

Janssen Biotech to Terminate Licensing Agreement with Astellas Pharma for ASP015K 80

Genmab Enters Into Licensing Agreement With Janssen Biotech For Daratumumab 81

ImmuNext Enters Into Licensing Agreement With Janssen Biotech 83

Genmab Enters Into Licensing Agreement With Janssen Biotech For DuoBody Technology 84

Phylogica Enters Into Licensing Agreement With Janssen Biotech For Phylomer Technology 84

Metamark Genetics Enters Into Licensing Agreement With Janssen Biotech 85

Janssen Biotech Enters Into Licensing Agreement With Pharmacyclics For PCI-32765 86

Topivert Enters into Licensing Agreement with RespiVert 88

AVEO Pharma Enters Into Licensing Agreement With Centocor Ortho Biotech 88

Janssen Biotech Enters Into Option To Acquire Amphivena From Affirmed Therapeutics 90

Janssen Biotech To Acquire Vascular Pharma, Diabetes Drug Developer 91

Janssen Biotech Inc, Key Competitors 93

Janssen Biotech Inc, Key Employees 94

Janssen Biotech Inc, Subsidiaries 95

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Janssen Biotech Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Janssen Biotech Inc (Janssen), formerly Centocor Ortho Biotech Inc. is a subsidiary of Johnson & Johnson, pharmaceutical company that manufactures, develops, and markets prescription drugs in immunology, nephrology and oncology areas. The company offers products such as stelara ustekinumab, simponi aria golimumab, remicade infliximab, procrit epoetin alfa, m doxil doxorubicin HCl liposome injection and zytiga abiraterone acetate. Its products are used for the treatment of infections that include muscle aches, cough, shortness of breath, fever, sweats, blood in phlegm, weight loss and stomach pain. The company also provides medical information database and reimbursement resources. Janssen is headquartered in Horsham, Pennsylvania, the US.

Janssen Biotech Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

Janssen Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11

Janssen Biotech Inc, Medical Devices Deals, 2011 to YTD 2017 13

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deal Details 19

Partnerships 19

Janssen Biotech Enters into Partnership with Bristol-Myers 19

Janssen Biotech Partners with Weill Cornell Medicine to Develop Prostate Cancer Therapies 19

Karolinska Institutet Partners with Johnson & Johnson Companies 20

Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 21

HitGen Enters into Agreement with Janssen Biotech 21

Innovative Targeting Solutions Enters into Research Agreement with Janssen Biotech 22

Philogen Enters into Co-Development Agreement with Janssen Biotech 23

Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech 24

Amyris Enters into Research Agreement with Janssen Biotech 24

Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 25

Enterome Bioscience Enters into Research Agreement with Janssen Biotech 26

Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 27

Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 27

Janssen Biotech Enters into Agreement with HUB foundation 28

Janssen Biotech Enters into Agreement with Eureka Therapeutics 29

Nuevolution Enters into Discovery Agreement with Janssen Biotech 29

enGene Enters into Agreement with Janssen Biotech 30

OICR and Novera Therapeutics Enter into Co-Development Agreement with Janssen Biotech 31

UbiVac Enters into Agreement with Janssen Biotech 32

Protectimmun Enters into Research Agreement with Janssen Biotech And Imperial College 33

Nextera Enters into Research Agreement with Janssen Biotech 33

Janssen Biotech Enters into Research Agreement with Emulate 34

X-Chem Expands Agreement with Janssen Biotech 35

Vectura Enters into Development and License Agreement with Janssen Biotech 36

Isis Pharma Enters into Agreement with Janssen Biotech to Discover and Develop RNA-Targeted Therapeutics 36

Atreca Enters into Research Agreement with Janssen Biotech 37

Weill Cornell Medical College Enters into Co-Development Agreement with Janssen Biotech and Johnson & Johnson Innovation 38

University of Texas MD Anderson Cancer Center Enters Into Co-Development Agreement With Johnson & Johnson Innovation And Janssen Biotech 39

Scholar Rock Enters Into Research Collaboration With Johnson & Johnson Innovation And Janssen Biotech 40

Capricor Enters Into Co-Development Agreement With Janssen For Cell Therapy For Cardiovascular Applications 41

Second Genome Enters Into Agreement With Janssen Biotech For Microbiome Drug Discovery 42

Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 43

Araxes Pharma Enters Into Drug Discovery Agreement With Janssen Biotech For Cancer 44

FORMA Therapeutics Enters Into Co-Development Agreement With Janssen Biotech 45

Molecular Partners Enters Into Research Agreement With Janssen Biotech 46

Topivert Enters into Drug Discovery Collaboration Agreement with RespiVert 47

Licensing Agreements 48

Janssen Biotech Enters into Licensing Agreement with Trianni 48

Janssen Biotech Enters into Licensing Agreement with Ablexis 48

CPDC Enters into Licensing Agreement with Janssen Biotech for Centyrin 49

Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 50

Janssen Biotec Enters into Licensing Agreement with MacroGenics 51

Janssen Biotech Enters into Licensing agreement with Tesaro 52

Janssen Biotech Exercises Option for Licensing Agreement with X-Chem 53

ViaCyte Enters into Licensing Agreement with Janssen Biotech 53

Janssen Biotech Exercises Option for Licensing Agreement with Scholar Rock 54

Janssen Biotech to Enter into Licensing Agreement with Alligator Bioscience for ADC-1013 55

Poseida Therapeutics Enters into Licensing Agreement with Janssen Biotech 56

Poseida Therapeutics Enters into Licensing Agreement with Janssen 57

Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 58

Applied Molecular Transport Enters into Licensing Agreement with Janssen Biotech 59

MacroGenics Enters into Licensing Agreement with Janssen Biotech for MGD011 59

Vedanta Biosciences Enters into Licensing Agreement with Janssen Biotech 61

Halozyme Therapeutics Enters into Licensing Agreement with Janssen Biotech 62

Geron Enters into Licensing Agreement with Janssen Biotech for Imetelstat 63

Modern Biosciences Enters into Licensing Agreement with Janssen Biotech 65

Transposagen BioPharma Enters into Licensing Agreement with Janssen Biotech 66

Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 67

Aduro BioTech Enters into Exclusive Licensing Agreement with Janssen Biotech 68

Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 69

Amunix Expands Licensing Agreement With Janssen For XTEN Technology 70

CSL Enters Into Licensing Agreement With Janssen For CSL-362 71

Genmab Expands Licensing Agreement With Janssen Biotech 72

Janssen Biotech Exercises Option for Licensing Agreement with OSE Immunotherapeutics 73

Amunix Exercises Option For Licensing Agreement With Janssen Biotech For XTEN Technology 74

Janssen Biotech Exercises Option For Licensing Agreement With Forma Therapeutics 75

Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 76

Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 77

Amunix Enters Into Licensing Agreement With Janssen Biotech For Proprietary XTEN Technology 78

Phenex Pharma Enters Into Licensing Agreement With Janssen Biotech For Retinoid-Acid Receptor-Related Orphan Receptor Gamma t Program 79

Janssen Biotech to Terminate Licensing Agreement with Astellas Pharma for ASP015K 80

Genmab Enters Into Licensing Agreement With Janssen Biotech For Daratumumab 81

ImmuNext Enters Into Licensing Agreement With Janssen Biotech 83

Genmab Enters Into Licensing Agreement With Janssen Biotech For DuoBody Technology 84

Phylogica Enters Into Licensing Agreement With Janssen Biotech For Phylomer Technology 84

Metamark Genetics Enters Into Licensing Agreement With Janssen Biotech 85

Janssen Biotech Enters Into Licensing Agreement With Pharmacyclics For PCI-32765 86

Topivert Enters into Licensing Agreement with RespiVert 88

AVEO Pharma Enters Into Licensing Agreement With Centocor Ortho Biotech 88

Acquisition 90

Janssen Biotech Enters Into Option To Acquire Amphivena From Affirmed Therapeutics 90

Janssen Biotech To Acquire Vascular Pharma, Diabetes Drug Developer 91

Janssen Biotech Inc-Key Competitors 93

Key Employees 94

Locations And Subsidiaries 95

Head Office 95

Other Locations & Subsidiaries 95

Appendix 96

Methodology 96

About GlobalData 96

Contact Us 96

Disclaimer 96


List Of Figure

List of Figures

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 9

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11

Janssen Biotech Inc, Medical Devices Deals, 2011 to YTD 2017 13


List Of Table

List of Tables

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Key Facts 1

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

Janssen Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Janssen Biotech Inc, Deals By Therapy Area, 2011 to YTD 2017 11

Janssen Biotech Inc, Medical Devices Deals, 2011 to YTD 2017 13

Janssen Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14

Janssen Biotech Enters into Partnership with Bristol-Myers 19

Janssen Biotech Partners with Weill Cornell Medicine to Develop Prostate Cancer Therapies 19

Karolinska Institutet Partners with Johnson & Johnson Companies 20

Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 21

HitGen Enters into Agreement with Janssen Biotech 21

Innovative Targeting Solutions Enters into Research Agreement with Janssen Biotech 22

Philogen Enters into Co-Development Agreement with Janssen Biotech 23

Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech 24

Amyris Enters into Research Agreement with Janssen Biotech 24

Mitsubishi Tanabe Pharma Enters into Distribution Agreement with Janssen Biotech 25

Enterome Bioscience Enters into Research Agreement with Janssen Biotech 26

Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 27

Janssen Biotech Enters into Research Agreement with David H. Koch Institute for Integrative Cancer 27

Janssen Biotech Enters into Agreement with HUB foundation 28

Janssen Biotech Enters into Agreement with Eureka Therapeutics 29

Nuevolution Enters into Discovery Agreement with Janssen Biotech 29

enGene Enters into Agreement with Janssen Biotech 30

OICR and Novera Therapeutics Enter into Co-Development Agreement with Janssen Biotech 31

UbiVac Enters into Agreement with Janssen Biotech 32

Protectimmun Enters into Research Agreement with Janssen Biotech And Imperial College 33

Nextera Enters into Research Agreement with Janssen Biotech 33

Janssen Biotech Enters into Research Agreement with Emulate 34

X-Chem Expands Agreement with Janssen Biotech 35

Vectura Enters into Development and License Agreement with Janssen Biotech 36

Isis Pharma Enters into Agreement with Janssen Biotech to Discover and Develop RNA-Targeted Therapeutics 36

Atreca Enters into Research Agreement with Janssen Biotech 37

Weill Cornell Medical College Enters into Co-Development Agreement with Janssen Biotech and Johnson & Johnson Innovation 38

University of Texas MD Anderson Cancer Center Enters Into Co-Development Agreement With Johnson & Johnson Innovation And Janssen Biotech 39

Scholar Rock Enters Into Research Collaboration With Johnson & Johnson Innovation And Janssen Biotech 40

Capricor Enters Into Co-Development Agreement With Janssen For Cell Therapy For Cardiovascular Applications 41

Second Genome Enters Into Agreement With Janssen Biotech For Microbiome Drug Discovery 42

Janssen Biotech Enters Into Agreement With CRT And ICR To Discover Multiple Myeloma Drug 43

Araxes Pharma Enters Into Drug Discovery Agreement With Janssen Biotech For Cancer 44

FORMA Therapeutics Enters Into Co-Development Agreement With Janssen Biotech 45

Molecular Partners Enters Into Research Agreement With Janssen Biotech 46

Topivert Enters into Drug Discovery Collaboration Agreement with RespiVert 47

Janssen Biotech Enters into Licensing Agreement with Trianni 48

Janssen Biotech Enters into Licensing Agreement with Ablexis 48

CPDC Enters into Licensing Agreement with Janssen Biotech for Centyrin 49

Janssen Biotech Enters into Licensing Agreement with Ionis Pharma 50

Janssen Biotec Enters into Licensing Agreement with MacroGenics 51

Janssen Biotech Enters into Licensing agreement with Tesaro 52

Janssen Biotech Exercises Option for Licensing Agreement with X-Chem 53

ViaCyte Enters into Licensing Agreement with Janssen Biotech 53

Janssen Biotech Exercises Option for Licensing Agreement with Scholar Rock 54

Janssen Biotech to Enter into Licensing Agreement with Alligator Bioscience for ADC-1013 55

Poseida Therapeutics Enters into Licensing Agreement with Janssen Biotech 56

Poseida Therapeutics Enters into Licensing Agreement with Janssen 57

Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 58

Applied Molecular Transport Enters into Licensing Agreement with Janssen Biotech 59

MacroGenics Enters into Licensing Agreement with Janssen Biotech for MGD011 59

Vedanta Biosciences Enters into Licensing Agreement with Janssen Biotech 61

Halozyme Therapeutics Enters into Licensing Agreement with Janssen Biotech 62

Geron Enters into Licensing Agreement with Janssen Biotech for Imetelstat 63

Modern Biosciences Enters into Licensing Agreement with Janssen Biotech 65

Transposagen BioPharma Enters into Licensing Agreement with Janssen Biotech 66

Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 67

Aduro BioTech Enters into Exclusive Licensing Agreement with Janssen Biotech 68

Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 69

Amunix Expands Licensing Agreement With Janssen For XTEN Technology 70

CSL Enters Into Licensing Agreement With Janssen For CSL-362 71

Genmab Expands Licensing Agreement With Janssen Biotech 72

Janssen Biotech Exercises Option for Licensing Agreement with OSE Immunotherapeutics 73

Amunix Exercises Option For Licensing Agreement With Janssen Biotech For XTEN Technology 74

Janssen Biotech Exercises Option For Licensing Agreement With Forma Therapeutics 75

Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 76

Phylogica Expands Licensing Agreement With Janssen Biotech For Peptide Drug Conjugates 77

Amunix Enters Into Licensing Agreement With Janssen Biotech For Proprietary XTEN Technology 78

Phenex Pharma Enters Into Licensing Agreement With Janssen Biotech For Retinoid-Acid Receptor-Related Orphan Receptor Gamma t Program 79

Janssen Biotech to Terminate Licensing Agreement with Astellas Pharma for ASP015K 80

Genmab Enters Into Licensing Agreement With Janssen Biotech For Daratumumab 81

ImmuNext Enters Into Licensing Agreement With Janssen Biotech 83

Genmab Enters Into Licensing Agreement With Janssen Biotech For DuoBody Technology 84

Phylogica Enters Into Licensing Agreement With Janssen Biotech For Phylomer Technology 84

Metamark Genetics Enters Into Licensing Agreement With Janssen Biotech 85

Janssen Biotech Enters Into Licensing Agreement With Pharmacyclics For PCI-32765 86

Topivert Enters into Licensing Agreement with RespiVert 88

AVEO Pharma Enters Into Licensing Agreement With Centocor Ortho Biotech 88

Janssen Biotech Enters Into Option To Acquire Amphivena From Affirmed Therapeutics 90

Janssen Biotech To Acquire Vascular Pharma, Diabetes Drug Developer 91

Janssen Biotech Inc, Key Competitors 93

Janssen Biotech Inc, Key Employees 94

Janssen Biotech Inc, Subsidiaries 95

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Janssen Biotech Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.